Moffitt Cancer Center Showcases Research and Innovation at 11th Annual Business of Biotech Conference

January 24, 2017

TAMPA, Fla. – Biotech startups working to make advances in cancer treatment and patient care will be spotlighted at Moffitt Cancer Center’s 11th annual Business of Biotech Conference: Partnering for the Future. The event, which brings together biomedical companies, startups, research organizations, entrepreneurs and investors, offers networking, collaboration and partnership opportunities. This year’s conference is Friday, Feb. 24, 8:30 a.m. – 3 p.m. in Moffitt’s Vincent A. Stabile Research Building.

“Since its launch in 2006, Business of Biotech has transformed into one of Florida’s forerunning conferences for the biotech community,” said Jarett Rieger, conference chairman and senior director of Moffitt’s Office of Innovation and Industry Alliances. “This conference is unique in its mission to further research that could be transformed into lifesaving treatments. Researchers, business professionals and investors benefit from the opportunity to create partnerships with others in their field that have creative and cutting edge ideas for the future.”

This year’s interview-style keynote address features George Golumbeski, Ph.D., who serves as the Executive Vice President of Business Development for Celgene Corporation. He is recognized as the major innovator behind Celgene’s well-regarded collaboration strategy and tactics and has been named one of the most influential people in the biotech industry. Former ABC correspondent and Moffitt Board of Advisors member, Sam Donaldson, will be interviewing Golumbeski and will lead the discussion on the facilitation of inter-company collaborations.

“We are delighted to have Dr. George Golumbeski as a speaker at this year’s conference,” said Rieger. “The Celgene Corporation has excelled in worldwide business development under the leadership of Golumbeski who is a man of influence, innovation and creativity. His advice will be beneficial for all those in pursuit of seeing growth in their research and business.”

In addition to Golumbeski’s appearance, the conference will include four breakout sessions on delivering medicine with nanoparticles, a portrait of partnership, patent strategies in the genomics era, and targeted clinical trials and the Oncology Research Information Exchange Network® (ORIEN).

There will also be tours of Moffitt Cancer Center’s hospital and research facilities on the Magnolia Campus and the presentation of two Moffitt Momentum Awards.

Business of Biotech is free and open to the public but seating is limited and reservations are required. To register, please visit http://bit.ly/2jc3Ibf.

About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, clinical trials, prevention and cancer control. Moffitt is the No. 6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2.5 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,200 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube

 

###